Novartis' Cosentyx (secukinumab) Receives the US FDA's Approval for Active Non-Radiographic Axial Spondyloarthritis
Shots:
- The approval is based on P-III PREVENT study assessing the safety and efficacy of Cosentyx (150mg with/out loading dose) vs PBO in 555 adult patients with active nr-axSpA that were biologic treatment naïve or had an inadequate response / were intolerant to an anti-tumor necrosis factor-α therapy (anti-TNFs)
- The P-III PREVENT study resulted in meeting its 1EPs i.e. 40% improvement in ASAS40 @52wks.; improvement in both load and without load arms @16wks. as assessed by ASQoL; @16wks. greater improvement from baseline in the SF-36 PCS score & MCS score; no new safety signals were detected
- Cosentyx is the first and only fully-human biologic targeting IL-17A and has received EMA’s approval for nr-axSpA in Apr’2020
Click here to read full press release/ article
Ref: Novartis | Image: Novartis
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com